Tim DraperFounder and Managing Partne, Draper Associate · I back the ideas that look crazy first

🧬 Disrupting the Lab: The Future of Clinical Trials and Customer Feedback 🚀

25 Mar 2024 · 1 min

Watch on YouTube

1:00

In this brief dialogue, two speakers discuss the status of an early-stage diagnostic product that measures hormones. They note that about 400 units have been shipped, providing initial real‑world data. Feedback from this first batch revealed that the minimum viable product, which only measured estrogen, is insufficient; additional hormones need to be included. The conversation then shifts to market implications, acknowledging that the product will disrupt traditional laboratory businesses and may upset incumbent labs. Finally, they consider the adoption challenge within hospitals, emphasizing that hospitals’ existing partnerships and contracts with large labs require a collaborative approach for the new product to be accepted.

How far are you, you know, within the clinical trials, the tests, the sample size, and all of that?
And what have you learned really? What have you heard from your customers? We've had some sales already, like 400 units were shipped. We learned from that first batch, just one hormone, which is the MVP about, the estrogen, is not enough. And exactly that, we need to put more hormones in there. Who would that upset, this product?
Who's gonna be upset? Who's not gonna like this product? Well, we exactly, yeah, we tend to say we're disrupting traditional lab business. Yeah, I mean, that's very true, but, uh, but is there Is there a way of collaborative approach? Because when a hospital makes a decision, they're going to think of their partnerships, their agreements, their contracts with these big labs, right?
They really look at the problems that we're trying to solve here as startups from a very, like, above perspective, and they really see the big picture. And that's, uh, we also can kind of bring our vision to the same level as they are.